TerSera Discusses Game-Changing Findings on Goserelin for Breast Cancer
Introduction to Goserelin in Breast Cancer Treatment
TerSera Therapeutics LLC has recently made notable strides in the fight against breast cancer with its groundbreaking presentation on goserelin. The innovative analyses showcased the treatment patterns of goserelin, a medication crucial in managing breast cancer, particularly in young women. This significant announcement took place at a prestigious symposium centered on quality care in oncology.
Study Overview and Objectives
The primary aim of this extensive study was to delve into the treatment experiences of female patients diagnosed with breast cancer who were treated using either the 3.6 mg or 10.8 mg doses of goserelin. By leveraging real-world evidence (RWE), TerSera set out to paint a clearer picture of how goserelin is utilized in clinical practice across the United States.
Methodology and Data Collection
To conduct this retrospective analysis, a comprehensive review of electronic health records through TriNetX was employed. This global healthcare research network provided valuable insights into the treatment patterns from January 2017 to December 2022, with follow-up continuing until March 15, 2024. The study garnered data from 3,620 patients, revealing how they interacted with goserelin therapies.
Insights on Patient Demographics
Among the identified patients, a substantial majority, 2,870, received the 3.6 mg dosage of goserelin. Additionally, 410 patients were treated with the 10.8 mg formulation, while 340 transitioned from the lower dose to the higher. Analyses captured vital patient demographics, adherence to treatment regimens, and utilization of healthcare resources.
Expert Commentary on Findings
Lonnie Brent, Pharm.D., who serves as the Senior Vice President of Medical and Scientific Affairs at TerSera Therapeutics, emphasized the significance of these findings. He remarked, "For young women with hormone-sensitive breast cancer at high risk of relapse, suppression of ovarian function is an essential component of their long-term treatment plan. This real-world evidence presented at the symposium enhances our comprehension of existing treatment patterns for young women receiving goserelin."
Regulatory Approvals and Indications
Goserelin, marketed as ZOLADEX, has received approval for various medical indications. The 3.6 mg and 10.8 mg formulations primarily manage hormone-sensitive conditions, including advanced breast and prostate cancers. Notably, ZOLADEX 3.6 mg also finds application in treating endometriosis and thinning the endometrium prior to surgical procedures.
Safety Profile and Adverse Effects
Like all therapeutic agents, goserelin comes with a spectrum of potential side effects. Among the most commonly reported reactions in clinical trials include hot flashes, decreased libido, and various symptoms associated with hormonal inhibition. Healthcare providers are encouraged to closely monitor patients for any adverse events and adjust treatment plans accordingly.
Importance of Ongoing Research
The outcomes from the ASCO symposium highlight an essential drive toward understanding how goserelin influences treatment outcomes. Research continues to shine a spotlight on how young patients manage breast cancer and the implications of treatment choices on long-term health and survivorship.
Conclusion on Treatment Patterns
As TerSera Therapeutics propels forward, the insights gained from this study will undoubtedly inform clinical strategies and patient care standards. The commitment to bolster understanding around treatment pathways for breast cancer using goserelin is not just a corporate objective; it is a promise to the many women affected by this diagnosis.
Frequently Asked Questions
What is goserelin?
Goserelin is a luteinizing hormone-releasing hormone agonist used to treat various hormone-sensitive cancers, including breast and prostate cancer.
What were the findings on goserelin treatment patterns?
The study revealed insights into how goserelin is utilized among young women with breast cancer, with a focus on adherence and healthcare resource utilization.
Why is ovarian function suppression important?
Suppressing ovarian function can significantly impact the long-term treatment outcomes for young women with hormone-sensitive breast cancer.
What side effects are associated with goserelin?
Common side effects include hot flashes, decreased libido, and mood changes, among others, which are associated with hormone therapy.
Where can I find more information about TerSera Therapeutics?
Information about TerSera and its ongoing research can be found on their official website.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.
Related Articles
- Burdette Beckmann Inc. Expands with EngageCPG Acquisition
- Charter Communications Expands Streaming Options for Customers
- Insights on the Recent Trends in Spanish Stock Market Activity
- Highlights from the Latest U.K. Stocks Market Performance
- Discover How AADS Transforms Cryptocurrency Ad Monetization
- Toyota's Strategic Preparations in Anticipation of Port Disruptions
- Understanding the Impact of Major Tech Stocks on the S&P 500
- Scarf Systems Achieves SOC 2 Type 2 Examination Success
- Introducing Velocity Checks: A New Frontier in Fraud Detection
- Air Liquide's Q3 2024 Sales Forecast Insights and Strategy
Recent Articles
- Why Redcare Pharmacy Stands Out in European ePharmacy Market
- Goldman Sachs Optimistic on S&P 500 Potential Beyond 6000
- Wind River's Helix Platform Achieves New FACE Technical Standard
- Sui Revolutionizes Blockchain Security with SCION Protocol
- Explore Innovative Connectivity at MWC with Boingo Wireless
- Nibiru Ventures: Empowering Blockchain Startups for Success
- Cloud Spending Surge: AI's Impact on Business Expenditures
- Top Dividend Stocks to Consider as Interest Rates Fall
- Transform Your Retail Strategy with Advanced Inventory Solutions
- Harnessing the Power of Redis with Memurai for Windows Users
- Pega's Global Expansion of Developer Training for Future Pros
- Stryten Energy Secures Major Funding for Vanadium Production
- Empowering Small Businesses: ShipEngine Integrates with QuickBooks
- Versetta Stone Triumphs in Good Housekeeping 2025 Awards
- Casey’s Celebrates Pizza Month with 4-H Support Initiative
- Venafi Enhances Machine Identity Security for Tomorrow's Needs
- Metomic Launches Revolutionary Solution for Data Protection
- Resonance Security Partners with NFL Star Jake Brendel
- Panasonic Connect Enhances Production with Auto Framing Tech
- Immix Biopharma's CAR-T NXC-201 Trial Shows Promising Results
- Morphotonics Welcomes Hugo da Silva as CEO to Innovate Growth
- Ansley Park Capital Achieves $200 Million in First Quarter
- Tarkett's Share Capital and Voting Rights Overview for Investors
- Vestigo Ventures Expands Investment in Roots Automation
- NeoVolta Expands Its Reach with $1.4 Million NREP Partnership
- Discover Innovative Lighting Solutions at NYControlled Event
- Lovisa Partners with Cart.com for Digital Marketing Growth
- Black Hills Corp. Gains Approval for New Natural Gas Rates
- 5E Advanced Materials Welcomes New VP to Enhance Growth Strategy
- Orum Therapeutics Takes Bold Step Towards KOSDAQ Listing
- Palantir Technologies and Edgescale AI Join Forces to Innovate
- Fraser Valley's Real Estate Shift Towards a Buyer-Friendly Market
- OptionMetrics Launches Enhanced IvyDB Implied Dividend Tool
- Southern Hills Home Buyers Celebrates 5-Star Customer Success
- Expanding Horizons: Malaysia's Prepaid Market Growth and Insights
- Exciting HGTV Urban Oasis Giveaway 2024 Now Open for Entries
- Empowering Women: No-Cost Breast Cancer Screenings Initiative
- Trend Shift: Top Cities Where Homes Sell Below Market Price
- Thompson Thrift Expands Yet Again with New Capital Partnership
- Thompson Thrift Launches Significant Multifamily Venture
- The Pickle Pad Expands with New Franchise Locations
- Adverity Unveils Innovative Data Quality Suite for Clients
- Co-Diagnostics, Inc. Showcases Innovations at UHCA/UCAL Expo
- Algolia Unveils Enhanced Crawler for Effortless Data Handling
- BWISE Hosts Networking Event for Health Equity and Innovation
- Krylon® Reveals Hammered Black as Its Next Iconic Color Choice
- Barilla Welcomes Exclusive Culinary Society of Chefs
- Remarkable Growth and Innovation at Swimming World Magazine
- Exclusive Culinary Experience at Barilla for Esteemed Chefs
- Daymond John Chooses Mindspace Wynwood for New Ventures